SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ORBIMED ADVISORS LLC	2. Date of Event Requiring Statement (Month/Day/Year) 05/08/2019		3. Issuer Name and Ticker or Trading Symbol <u>NextCure, Inc.</u> [NXTC]				
(Last) (First) (Middle) C/O NEXTCURE, INC. 9000 VIRGINIA MANOR ROAD, SUITE 200			4. Relationship of Reporting Perso (Check all applicable) X Director X Officer (give title below)	on(s) to Issue 10% Owne Other (spe below)	er ecify 6.	Ionth/Day/Year)	ate of Original Filed t/Group Filing (Check
(Street) BELTSVILLE MD 20705							y One Reporting Person y More than One erson
(City) (State) (Zip)	Table I No	n Dorivati	ive Securities Beneficial	w Ownod			
1. Title of Security (Instr. 4)			Amount of Securities eneficially Owned (Instr. 4)	3. Ownership 4.		I. Nature of Indirect Beneficial Ownership Instr. 5)	
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Security		4. Conversio or Exercis	e Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)	
Series A-1 Preferred Stock	(1)	(1)	Common Stock	445,866	(1)	I	See footnotes ⁽²⁾⁽³⁾
Series A-2 Preferred Stock	(1)	(1)	Common Stock	743,110	(1)	I	See footnotes ⁽²⁾⁽³⁾
Series A-3 Preferred Stock	(1)	(1)	Common Stock	729,599	(1)	I	See footnotes ⁽²⁾⁽³⁾
Series B-1 Preferred Stock	(1)	(1)	Common Stock	442,438	(1)	I	See footnotes ⁽²⁾⁽³⁾
1. Name and Address of Reporting Person* ORBIMED ADVISORS LLC				ż			
(Last) (First) (Middle C/O NEXTCURE, INC. 9000 VIRGINIA MANOR ROAD, SUITE 200)	_					
(Street) BELTSVILLE MD 20705		_					
(City) (State) (Zip)							
1. Name and Address of Reporting Person [*] OrbiMed Capital GP VI LLC							
(Last) (First) (Middle C/O NEXTCURE, INC.)						
9000 VIRGINIA MANOR ROAD, SUITE 200	_						
(Street) BELTSVILLE MD 20705		_					
(City) (State) (Zip)							

Explanation of Responses:

1. The reported securities are convertible into shares of Common Stock on a 1-for-8.0338 basis at the holder's election, will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering, and have no expiration date.

2. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP LLC ("GP VII") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein.

3. This report on Form 3 is jointly filed by GP VI and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Chau Q. Khuong "(Khuong"), an employee of OrbiMed advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Khuong is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or any other purpose.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Douglas Coon, Chief **Compliance Officer**

05/08/2019

/s/ Douglas Coon, Chief **Compliance Officer** Date

05/08/2019

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.